Methyl 5-bromo-1H-indazole-4-carboxylate, 95.0%, 5g

1-Methoxy-4-nitrobenzene, 97.0%, 25g

Etilenglicol monobutil éter, 99% min, para síntesis, 2,5 L, envase de vidrio

2-(4-Chlorophenyl)-5-methyl-1,3,4-oxadiazole, 95+%, 100mg

(S)-(+)-alpha-Methoxyphenylacetic Acid>98.0%(GC)(T)5g

2-Amino-5-chlorobenzoic acid, 99.00%, 25g

1-Boc-4-(piperidin-4-yl)-piperazine, 98.0%, 25g

17-oxapentacyclo[6.6.5.0~2,7~.0~9,14~.0~15,19~]nonadeca-2,4,6,9,11,13-hexaene-16,18-dione, 1g

[4-(4-Fluoro-phenyl)-pyridin-2-yl]-methanol, 95.0%, 1g

METHYL N-BOC-O-METHYL-L-TYROSINATE, 97.0%, 1g

Columna capilar GC ROTI®Cap-1701, 25 m, 0,32 mm, 0,35 µm, 1 Pieza(s)

4-NITROPHENYLACETONE, 95.0%, 100g

3-methyl-6-phenyl-2,5-dihydro-1,2,4-triazin-5-one, 97%, 250mg